skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 408  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: Congenital Diseases remove subject: Disease remove subject: Pharmaceutical Industry remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
Material Type:
Article
Add to My Research

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

MMWR. Morbidity and mortality weekly report, 2022-01, Vol.71 (4), p.109-117

COPYRIGHT 2022 U.S. Government Printing Office ;Published 2022. This article is a U.S. Government work and is in the public domain in the USA. ;ISSN: 0149-2195 ;EISSN: 1545-861X ;DOI: 10.15585/mmwr.mm7104a1 ;PMID: 35085226

Full text available

2
Nationwide comprehensive epidemiological study of rare diseases in Japan using a health insurance claims database
Material Type:
Article
Add to My Research

Nationwide comprehensive epidemiological study of rare diseases in Japan using a health insurance claims database

Orphanet journal of rare diseases, 2022-03, Vol.17 (1), p.140-140, Article 140 [Peer Reviewed Journal]

2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-022-02290-0 ;PMID: 35346288

Full text available

3
Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database
Material Type:
Article
Add to My Research

Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database

Drug safety, 2017-11, Vol.40 (11), p.1141-1146 [Peer Reviewed Journal]

Springer International Publishing AG 2017 ;Copyright Springer Nature B.V. Nov 2017 ;ISSN: 0114-5916 ;EISSN: 1179-1942 ;DOI: 10.1007/s40264-017-0560-z ;PMID: 28664356

Full text available

4
Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database
Material Type:
Article
Add to My Research

Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database

Health science reports, 2022-11, Vol.5 (6), p.e931-n/a [Peer Reviewed Journal]

2022 The Authors. published by Wiley Periodicals LLC. ;2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2398-8835 ;EISSN: 2398-8835 ;DOI: 10.1002/hsr2.931

Full text available

5
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries
Material Type:
Article
Add to My Research

Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries

Pharmaceutical medicine, 2020-02, Vol.34 (1), p.31-38 [Peer Reviewed Journal]

The Author(s) 2019 ;Copyright Springer Nature B.V. Feb 2020 ;ISSN: 1178-2595 ;EISSN: 1179-1993 ;DOI: 10.1007/s40290-019-00316-w ;PMID: 32048210

Full text available

6
Antimicrobial Agent Dosing in Infants
Material Type:
Article
Add to My Research

Antimicrobial Agent Dosing in Infants

Clinical therapeutics, 2016-09, Vol.38 (9), p.1948-1960 [Peer Reviewed Journal]

Elsevier HS Journals, Inc. ;2016 Elsevier HS Journals, Inc. ;Copyright © 2016 Elsevier HS Journals, Inc. All rights reserved. ;Copyright Elsevier Limited Sep 2016 ;ISSN: 0149-2918 ;EISSN: 1879-114X ;DOI: 10.1016/j.clinthera.2016.06.017 ;PMID: 27473383

Full text available

7
The relationship of psoriasis and melanocytic nevi
Material Type:
Article
Add to My Research

The relationship of psoriasis and melanocytic nevi

Indian journal of dermatology, 2016-11, Vol.61 (6), p.664-667 [Peer Reviewed Journal]

COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd. ;Copyright Medknow Publications & Media Pvt Ltd Nov-Dec 2016 ;Copyright: © Indian Journal of Dermatology 2016 ;ISSN: 0019-5154 ;EISSN: 1998-3611 ;DOI: 10.4103/0019-5154.193680 ;PMID: 27904187

Full text available

8
Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden
Material Type:
Article
Add to My Research

Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden

Clinical and translational science, 2014-08, Vol.7 (4), p.297-299 [Peer Reviewed Journal]

2014 Wiley Periodicals, Inc. ;Copyright John Wiley & Sons, Inc. Aug 2014 ;ISSN: 1752-8054 ;EISSN: 1752-8062 ;DOI: 10.1111/cts.12163 ;PMID: 24816032

Digital Resources/Online E-Resources

9
Press Release: Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Material Type:
Newsletter Article
Add to My Research

Press Release: Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 22, 2024

Digital Resources/Online E-Resources

10
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

11
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

12
Anvisa approves drug that prevents respiratory virus in babies
Material Type:
Newsletter Article
Add to My Research

Anvisa approves drug that prevents respiratory virus in babies

CE Noticias Financieras, 2023

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

13
Press Release: Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
Material Type:
Newsletter Article
Add to My Research

Press Release: Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

Dow Jones Institutional News, 2021

Copyright Dow Jones & Company Inc Mar 12, 2021

Digital Resources/Online E-Resources

14
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

NASDAQ OMX's News Release Distribution Channel, 2021

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

15
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
Material Type:
Newsletter Article
Add to My Research

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

16
Crinetics Pharmaceuticals Reports Top-Line Results Including Strong Adrenal Suppression From CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals Reports Top-Line Results Including Strong Adrenal Suppression From CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

Benzinga Newswires, 2022

2020 Benzinga.com - Benzinga does not provide investment advice. All rights reserved.

Digital Resources/Online E-Resources

17
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
Material Type:
Newsletter Article
Add to My Research

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

NASDAQ OMX's News Release Distribution Channel, 2022

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

18
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

News Bites US - NASDAQ, 2020

Copyright News Bites Pty Ltd Sep 22, 2020

Digital Resources/Online E-Resources

19
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
Material Type:
Newsletter Article
Add to My Research

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

News Bites US - NASDAQ, 2022

Copyright News Bites Pty Ltd May 26, 2022

Digital Resources/Online E-Resources

20
Advancement of gene therapies increases pharmaceutical industry pressure on heel testing
Material Type:
Newsletter Article
Add to My Research

Advancement of gene therapies increases pharmaceutical industry pressure on heel testing

CE Noticias Financieras, 2022

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

Results 1 - 20 of 408  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2009  (3)
  2. 2009 To 2013  (7)
  3. 2014 To 2016  (36)
  4. 2017 To 2020  (223)
  5. After 2020  (140)
  6. More options open sub menu

Searching Remote Databases, Please Wait